PD-1/PD-L1抑制剂对肺鳞状细胞癌患者调节性T细胞及其亚型的影响

摘要 目的：探讨PD-1/PD-L1抑制剂对肺鳞状细胞癌（鳞癌）患者调节性T细胞（Regulatory T cell,Treg细胞）及其亚型的影响。方法：2019年1月至2020年12月来我院就诊的肺鳞癌初诊患者纳入本项研究;患者均接受Nivolumab治疗,根据治疗效果不同,将患者分为缓解组（n=20）和无效组（n=20）;流式细胞术检测外周血总Treg细胞、PD-1+Treg细胞、CD150+Treg细胞、CTLA-4+Treg细胞、LAG-3+Treg细胞的比例。结果：缓解组外周血总Treg细胞、CTLA-4+Treg细胞和LAG-3+Treg细胞的比例分别为4.052±0.231%、1.616±0.099%和0.328±0.021%,无效组的比例分别为5.532±0.395%、3.277±0.224%和0.857±0.108%,差异均具有显著的统计学意义（t=3.239,P=0.009;t=6.776,P＜0.001;t=4.807,P＜0.001）;缓解组外周血PD-1+Treg细胞和CD150+Treg细胞的比例分别为0.195±0.016%和1.530±0.113%,无效组的比例分别为0.203±0.018%和1.787±0.157%,差异均不具有统计学意义（t=0.318,P=0.757;t=1.329,P=0.214）。结论：PD-1/PD-L1抑制剂治疗无效的肺鳞癌患者外周血总Treg细胞、CTLA-4+Treg细胞和LAG-3+Treg细胞的比例均显著升高。

Effects of PD-1/PD-L1 Inhibitor on Regulatory T Cells and Their Subtypes in Patients with Lung Squamous Cell Carcinoma

ABSTRACT Objective: To investigate the effects of PD-1/PD-L1 inhibitor on regulatory T cells (Treg cells) and their subtypes in patients with lung squamous cell carcinoma. Methods: Newly diagnosed patients with lung squamous cell carcinoma admitted to our hospital from January 2019 to December 2020 were included in this study. All patients received Nivolumab, and were divided into remission group (n=20) and ineffective group (n=20) according to different therapeutic effects. Flow cytometry was used to detect the proportion of total Treg cells, PD-1+Treg cells, CD150+Treg cells, CTLA-4+Treg cells, and LAG-3+Treg cells in peripheral blood. Results: The proportions of total Treg cells, CTLA-4+Treg cells and LAG-3+Treg cells in the remission group were 4.052±0.231%, 1.616±0.099% and 0.328±0.021%, respectively, and those in the ineffective group were 5.532±0.395%, 3.277±0.224% and 0.857±0.108%, respectively, the differences were statistically significant (t=3.239, P=0.009; t=6.776, P<0.001; t=4.807, P<0.001). The proportions of PD-1+Treg cells and CD150+Treg cells in the remission group were 0.195±0.016% and 1.530±0.113%, respectively, and those in the ineffective group were 0.203±0.018% and 1.787±0.157%, respectively, with no statistically significant differences (t=0.318, P=0.757; t=1.329, P=0.214). Conclusion: The proportions of total Treg cells, CTLA-4+Treg cells and LAG-3+Treg cells in peripheral blood of patients with lung squamous cell carcinoma who did not respond to PD-1/PD-L1 inhibitors were significantly increased.